Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Errik Anderson
AddedFeb 15, 2024
UpdatedMay 31, 2026
Errik Anderson

Errik Anderson

Board Member, Adimab

CrunchbaseLinkedInThe Org

Errik Anderson's Career

Adimab
Adimab

Lebanon, NH, US

Board Member· Board
Alloy Therapeutics
Alloy Therapeutics

Waltham, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Errik Anderson's Career

Adimab
Adimab
Public$45.5M1492007Lebanon, NH, US
Board Member· Board

Leadership at Adimab

Fran HellerFran HellerBoard Member
Tillman GerngrossTillman GerngrossBoard Member
K. Dane WittrupK. Dane WittrupBoard Member
Carl L. GordonCarl L. GordonBoard Member
Terry McguireTerry McguireBoard Member
Philip ChasePhilip ChaseBoard Member
Alloy Therapeutics
Alloy Therapeutics
Series D$128.3M1342017Waltham, MA, US
Board Member· Board

Leadership at Alloy Therapeutics

Alaa HalawaAlaa HalawaBoard Member
Fabian HansenFabian HansenBoard Member

Similar to Alloy Therapeutics

OmniAbOmniAbEmeryville, CA, USAntibody Discoveryest. 2021OmniAbEmeryville, CA, US · est. 2021

OmniAb: Your pharmaceutical partner in discovering next-generation therapeutics through diverse antibody repertoires.

Public · $70M175
Allyx TherapeuticsAllyx TherapeuticsNew Haven, CT, USTherapeuticsest. 2018Allyx TherapeuticsNew Haven, CT, US · est. 2018

Allyx Therapeutics: Clinical-stage biotech firm developing therapies to combat Alzheimer's disease.

Seed · $10.1M4
Parallel BioParallel BioCambridge, MA, USDrug Discoveryest. 2021Parallel BioCambridge, MA, US · est. 2021

Parallel Bio: Human immune system platform for drug and vaccine testing.

Seed · $4.6M9
AltruBioAltruBioLos Altos, CA, USAntibody Therapeuticsest. 2000AltruBioLos Altos, CA, US · est. 2000

AltruBio, a global biotech firm, develops targeted antibody therapeutics for cancer and immune diseases.

Series A · $102.6M5

Errik Anderson's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Errik Anderson

Ali ForsythAli ForsythCo-Founder · Alloy EnterprisesMatthew C. DiamondMatthew C. DiamondBoard Member · GenescoRaj ChoudhuryRaj ChoudhuryBoard Member · CooleafJoel BealJoel BealCo-Founder · AlloyMax DarlingMax DarlingCo-Founder · Alloy LEDLaura SpiekermanLaura SpiekermanCo-Founder · Alloy